Patents by Inventor Ulf PETRAUSCH

Ulf PETRAUSCH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of HLA-B27 homodimers for cancer treatment
    Patent number: 11484572
    Abstract: The invention relates to a HLA-B27 Fc open conformer or a HLA-B27 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B27 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B27 Fc open conformer and immune checkpoint inhibitors.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: November 1, 2022
    Assignees: UNIVERSITÄT BASEL, UNIVERSITÄT ZURICH
    Inventors: Osiris Marroquin Belaunzaran, Christoph Renner, Ulf Petrausch
  • HLA-B57 OPEN CONFORMERS
    Publication number: 20220339250
    Abstract: The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents. Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.
    Type: Application
    Filed: June 26, 2022
    Publication date: October 27, 2022
    Applicants: UNIVERSITAT ZURICH, UNIVERSITAT BASEL
    Inventors: Osiris MARROQUIN BELAUNZARAN, Ulf PETRAUSCH, Christoph RENNER
  • Method of treating cancer with an HLA-B57 open conformer
    Patent number: 11369660
    Abstract: The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents. Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+ T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.
    Type: Grant
    Filed: March 7, 2017
    Date of Patent: June 28, 2022
    Assignees: UNIVERSITAT ZURICH, UNIVERSITAT BASEL
    Inventors: Osiris Marroquin Belaunzaran, Ulf Petrausch, Christoph Renner
  • HLA-B57 OPEN CONFORMERS
    Publication number: 20190247466
    Abstract: The invention relates to a HLA-B57 open conformer or a HLA-B57 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B57 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B57 Fc open conformer and immune checkpoint inhibitors and/or checkpoint agonist agents. Furthermore, the invention relates to the use of HLA-B57 open conformer as an immunomodulator, particularly in diseases where modulation of diverse immune cell components (e.g. cytotoxic CD8+ T cells, Tregs) is a therapeutic strategy, e.g. infectious diseases.
    Type: Application
    Filed: March 7, 2017
    Publication date: August 15, 2019
    Applicants: UNIVERSITAT ZURICH, UNIVERSITAT BASEL
    Inventors: Osiris MARROQUIN BELAUNZARAN, Ulf PETRAUSCH, Christoph RENNER
  • USE OF HLA-B27 HOMODIMERS FOR CANCER TREATMENT
    Publication number: 20180028606
    Abstract: The invention relates to a HLA-B27 Fc open conformer or a HLA-B27 Fc fusion protein for use in the treatment or prevention of cancer. The Fc open conformer comprises or consists of a first and a second monomer, and each monomer comprises a HLA-B27 chain. The Fc fusion protein further comprises a protein stabilizing polypeptide sequence and optionally an amino acid linker. Further aspects of the invention provide combination medicaments comprising the HLA-B27 Fc open conformer and immune checkpoint inhibitors.
    Type: Application
    Filed: August 4, 2017
    Publication date: February 1, 2018
    Applicants: UNIVERSITAT ZURICH, UNIVERSITAT BASEL
    Inventors: Osiris MARROQUIN BELAUNZARAN, Christoph RENNER, Ulf PETRAUSCH